Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2008

View Archived Issues

Adherex presents phase I/II results on ADH-1, a novel N-cadherin-targeting oncolytic

New treatment options for cancer reported in recent patent literature

Gradalis reports on novel autologous tumor cell vaccine for advanced cancer

Hana's phase II Marqibo trial meets clinical response criteria

Synosia commences phase IIa trial for potential first-in-class treatment for PD

FDA grants approval to Ark Therapeutics' SPA and IND for phase III trial of Trinam in ESRD

Locus enters research collaborations for p38 inhibitors

Daiichi Sankyo launches Gracevit tablets in Japan

ProStrakan presents an update on FDA's review of NDA for Sancuso in CINV

Bavarian Nordic enters clinical trials with prostate cancer vaccine

MDX-1100 safe and well tolerated in phase I study

Immune and clinical responses seen with CTL vaccine IDM-2101 in non-small cell lung cancer

Phase I study shows safety of E-7820 and cetuximab combination in solid tumor patients

Inflammation and joint destruction inhibited in arthritis mouse model by ABD-345

CHMP issues positive opinion for Sugammadex in reversal of muscle relaxants

Rexahn commences phase II trial for Zoraxel to treat erectile dysfunction

Calando doses first patient in siRNA phase I clinical trial

Acorda announces positive phase III Fampridine-SR data in patients with MS

Altus reports top-line results from ALTU-237 phase I clinical trial

Recent Kowa patent describes new agents for respiratory disorders

Novel therapeutic agents for osteoporosis disclosed in recent Wyeth patents

Auxilium's Xiaflex meets primary endpoint in pivotal phase III study

PsychoGenics announces positive phase IIa data for eltoprazine in ADHD

AstraZeneca submits sNDA for Symbicort for treating asthma in children as young as age six

Sunesis focuses resources on voreloxin development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.